Add BrightSurf on Google Email

3D-patient tumor avatars: Maximizing their potential for next-generation precision oncology

The use of 3D-patient tumor avatars (3D-PTAs) is crucial for guiding treatment decisions in precision oncology. These avatars, including patient-derived organoids, 3D bioprinting, and microscale models, can accurately depict a tumor with its microenvironment, enabling the testing and prediction of therapeutic drug efficacy.

SourceTerasaki Institute for Biomedical Innovation·JournalCancer Cell·TypeCommentary/editorial·DateDec 20, 2022

Four decades of NCI-funded NCTN trials: 14.2 million life-years, at $326 per year

The study estimated that the NCI-funded NCTN trials have added at least 14.2 million life-years to cancer patients in the US, representing a cost of $326 per year. The trials have had a significant impact on clinical care, with 87.7% of their findings cited as evidence in guidelines and package inserts.

SourceSWOG Cancer Research Network·JournalJournal of Clinical Oncology·TypeData/statistical analysis·DateDec 19, 2022

VA’s new “burden-free” study method finds two blood pressure drugs equally effective

A large VA clinical trial found that chlorthalidone (CTD) was not superior to hydrochlorothiazide (HCTZ) for preventing cardiovascular disease or non-cancer death. The study enrolled over 13,500 Veterans with high blood pressure and showed no difference between the two drugs in terms of effectiveness.

SourceVeterans Affairs Research Communications·JournalNew England Journal of Medicine·TypeRandomized controlled/clinical trial·DateDec 14, 2022

Updated clinical trial reporting guidelines include patient voices to improve trial utility and transparency

The updated guidelines aim to increase impact and improve research integrity by defining and measuring outcomes in clinical trials. The new extensions include nine outcome-specific items that should be defined in all trial protocols and 17 additional items to address in published reports, ensuring transparency and relevance for patients.

Novel method with implications for treatment of Fukuyama muscular dystrophy, a widespread neuromuscular disorder

Researchers from Japan have developed an RNA interference method using antisense oligonucleotides to correct a genetic defect in Fukuyama Muscular Dystrophy. This approach has shown promise in treating patients with the disease, which is characterized by generalized muscle weakness and intellectual disability.

SourceFujita Health University·JournalHuman Molecular Genetics·TypeExperimental study·DateDec 12, 2022

A unique clinical trial leads to a dramatic decrease in early deaths from the rare and aggressive—yet highly curable—acute promyelocytic leukemia (APL)

A unique clinical trial has achieved a remarkable 97% induction survival rate in patients with acute promyelocytic leukemia (APL) by providing a simplified treatment regimen and 24/7 support from APL experts. This collaborative care model, known as EA9131, significantly reduced early deaths and improved overall survival rates.

Experimental cancer therapy shows success in more than 70% of patients in global clinical trials

Researchers from The Mount Sinai Hospital found that talquetamab, a bispecific antibody, was successful in killing multiple myeloma cells in over 70% of patients. This therapy directs the immune system to target cancer cells and has shown promise even for those who have resisted all other treatments.

SourceThe Mount Sinai Hospital / Mount Sinai School of Medicine·JournalNew England Journal of Medicine·DateDec 10, 2022

Let the patient choose their type 2 diabetes medication says research study

A new study allows people with type 2 diabetes to choose their own medication after trying three different drugs in succession. The approach resulted in better glucose control and fewer side effects compared to other methods. Researchers conclude that patients should try before choosing a treatment for optimal results.

SourceUniversity of Exeter·JournalNature Medicine·TypeRandomized controlled/clinical trial·DateDec 7, 2022

Understanding how the perception of risks and benefits influence cancer clinical trial withdrawal outcomes

A new investigation from the University of Pennsylvania School of Nursing found that patients perceived important benefits from Cancer Clinical Trials (CCT) participation, which was associated with trial retention. The study suggests that understanding these perceptions is crucial for improving trial retention rates.

Cochrane review of COVID-19 vaccines shows they are effective

The Cochrane review analyzed data from 41 randomized controlled trials of 12 different COVID-19 vaccines, involving 433,838 people worldwide. The review found that most vaccines reduced the risk of COVID-19 infection and severe disease, with few reported side effects.

SourceWiley·JournalCochrane Database of Systematic Reviews·DateDec 6, 2022

Trial compares therapies for reducing cardiovascular risk among people with rheumatoid arthritis

A randomized clinical trial found that two anti-inflammatory strategies reduced disease activity and arterial inflammation in patients with moderate to high rheumatoid arthritis. The treatments had no differences in cardiovascular risk reduction, highlighting the importance of specific clinical trials for this population.

SourceBrigham and Women's Hospital·JournalAnnals of the Rheumatic Diseases·TypeObservational study·DateDec 5, 2022

Clover’s vaccine candidate reduced household transmission of SARS-CoV-2 in study published in Clinical Infectious Diseases

A global Phase 2/3 clinical trial found that vaccination with SCB-2019 reduced the risk of transmitting SARS-CoV-2 infection to household members. The study showed a significant reduction in symptomatic cases among vaccinated household contacts and indicated that vaccines can play an important role in controlling future outbreaks.

SourceInternational Vaccine Institute·JournalClinical Infectious Diseases·TypeRandomized controlled/clinical trial·DateNov 30, 2022

Oncotarget | Association of fall rate and functional status by APOE genotype in cancer survivors after exercise intervention

A study published in Oncotarget found that APOE genotype is associated with the presence and severity of cancer treatment-related side effects and symptoms, as well as the response to exercise-based interventions in cancer survivors. ApoE4 carriers showed a lower fall rate after exercise intervention compared to non-carriers.

SourceImpact Journals LLC·JournalOncotarget·TypeObservational study·DateNov 22, 2022

SWOG researchers to present 10 abstracts at 2022 San Antonio Breast Cancer Symposium

Researchers from the SWOG Cancer Research Network presented several abstracts at the 2022 San Antonio Breast Cancer Symposium. Two trials found that adding one year of everolimus to adjuvant endocrine therapy did not improve IDFS or OS for HR+, HER2- breast cancer patients, but premenopausal patients showed statistically significant lo...

SourceSWOG Cancer Research Network·TypeRandomized controlled/clinical trial·DateNov 21, 2022

Oncotarget | Mutation analysis performed on tumor biopsies from patients with newly-diagnosed germinal center aggressive B cell lymphomas

A new study analyzed tumor biopsies from patients with newly-diagnosed germinal center B cell lymphoma and found that CREBBP mutations were associated with lower disease-free survival rates. The researchers identified CLMA as a practical tool to translate experimental findings into clinical applications.

SourceImpact Journals LLC·JournalOncotarget·TypeExperimental study·DateNov 17, 2022

Longest follow-up of patients with early breast cancer shows radiotherapy does not improve survival after 30 years

A 30-year follow-up study of patients with early breast cancer found that radiotherapy does not improve overall survival rates after 10 years but reduces the risk of recurrence in the same breast. The study's findings challenge traditional concepts of long-term anti-cancer benefits of radiotherapy.

SourceEuropean Organisation for Research and Treatment of Cancer·TypeRandomized controlled/clinical trial·DateNov 17, 2022

Weak evidence that interventions to boost housing affordability and stability promote better health

Research on interventions to mitigate housing insecurity found low-certainty evidence of positive health outcomes, primarily for emergency rent assistance and homeownership assistance. However, existing interventions may need to be paired with other efforts to address structural determinants of health.

SourceUniversity of California - Los Angeles Health Sciences·JournalJAMA Network Open·TypeMeta-analysis·DateNov 16, 2022

Oral deucravacitinib benefits patients with lupus

A phase 2 clinical trial has generated promising results for deucravacitinib, an oral inhibitor of tyrosine kinase 2 (TYK2), in patients with active lupus. The study found that patients treated with deucravacitinib experienced significant improvements in disease activity, with response rates ranging from 34% to 58% compared to placebo.

SourceWiley·JournalArthritis & Rheumatology·DateNov 12, 2022

Anifrolumab shows long-term promise in patients with lupus

Researchers report positive results from the first placebo-controlled trial of anifrolumab, a human monoclonal antibody targeting type I interferon receptor in patients with lupus. Treatment with anifrolumab was well-tolerated and sustained reduction in lupus disease activity.

SourceWiley·JournalArthritis & Rheumatology·DateNov 12, 2022

Go home safe: fall prevention for older hospital patients after discharge

A study by Osaka Metropolitan University found that teaching fall prevention using home floor plans reduced falls in older hospital patients by 97% compared to a control group. The intervention group had no falls within two months of discharge, while the control group experienced 7.7% falls.

SourceOsaka Metropolitan University·JournalInternational Journal of Environmental Research and Public Health·TypeRandomized controlled/clinical trial·DateNov 10, 2022

Latest neural signals recorded with ABILITY brain-computer interface and new details of the system presented at Society for Neuroscience meeting

The Wyss Center's ABILITY system, a fully implantable brain-computer interface, records neural activity in sheep with high accuracy, decoding fine movement intention from small brain areas. The device is designed to improve quality of life and independence for people with severe paralysis.